EGFR-TKIs在晚期EGFR受体突变肺鳞癌患者中的临床应用  

Clinical efficacy of EGFR-TKIs for advanced squamous-cell lung cancer patients with EGFR mutations

作　　者：吴洪波[1] 李明智[1] 史亮[1] 陶虹[1] 唐俊舫[1] 刘喆[1] 

机构地区：[1]首都医科大学附属北京胸科医院肿瘤科,北京市101149

出　　处：《中国肿瘤临床》2016年第24期1103-1105,共3页Chinese Journal of Clinical Oncology

摘　　要：目的:探讨表皮生长因子受体酪氨酸激酶抑制剂(epidermal growth factor receptor tyrosine kinase inhibitors,EGFR-TKIs)对具有表皮生长因子受体(epidermal growth factor receptor,EGFR)突变的晚期肺鳞癌患者临床疗效。方法:回顾性分析首都医科大学附属北京胸科医院2010年1月至2016年7月收治的2 317肺鳞癌患者,筛选出有明确随访记录的7例确诊具有EGFR突变的肺鳞癌患者,使用EGFR-TKI如吉非替尼、厄洛替尼治疗,直至疾病进展(progressive disease,PD)。结果:使用EGFR-TKI治疗后,患者客观缓解率(objectire response rate,ORR)42.9%,疾病控制率(disease control rate,DCR)100%(7/7),中位无进展生存期6.1个月。结论:EGFR-TKI对EGFR突变的肺鳞癌患者具有一定临床疗效。但本研究病例数少仅有7例,亟需更多的病例来进行补充研究及验证上述结论。Objective： To investigate the clinical efficacy of epidermal growth factor receptor tyrosine kinase inhibitors （EGFR-TKIs） in the treatment of squamous-cell lung cancer patients with EGFR mutations. Methods： We screened out seven patients who were diagnosed with EGFR mutations and received EGFR-TKIs, such as gifitinib or erlotinib, from 2,317 squamous-cell lung cancer patients treated at the Beijing Chest Hospital from January 2010 to July 2016. Results： After using EGFR-TKIs, the objective response rate was 42.9%, the disease control rate was 100%, and the median progression-free survival was 6.1 months. Conclusion： EGFR-TKIs exert a certain clinical curative effect on patients with EGFR mutations in squamous-cell lung cancer. However, given that only seven cases are presented in this research group, more cases are needed for further research to verify the above conclusion.

关 键 词：表皮生长因子受体 酪氨酸激酶抑制剂 肺鳞状细胞癌 基因突变 

分 类 号：R734.2[医药卫生—肿瘤]